Rheumatoid factor value for determining the first biologic agent to use for non-systemic juvenile idiopathic arthritis
© Japan College of Rheumatology 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
OBJECTIVES: Currently, no indicators on which biologic disease-modifying anti-rheumatic drugs (bDMARDs) should be used first for juvenile idiopathic arthritis (JIA) have been established. Thus, this study aimed to determine the useful biomarkers in JIA to enable the best selection of the first bDMARDs without primary failure.
METHODS: This retrospective study used data of patients examined for JIA between 2015 and 2021 at Kagoshima University Hospital in Japan.
RESULTS: Altogether, 67 cases of non-systemic JIA were analyzed, excluding cases that had been treated for <6 months. Of the 67 cases, 52 were treated with bDMARDs and all rheumatoid factor (RF)+ types (32 cases) were treated with bDMARDs. Eleven cases (31.4&) (all were RF+ types and used anti-tumor necrosis factor (TNF)α agents) switched to other bDMARDs because of primary failure, and nine cases had secondary failure (6;anti-TNF, 3;anti-Interleukin-6). A significant difference in pre-treatment RF values (177.9 vs 25.7 IU/ml, p = 0.002) and presence (Odds Ratio 1.952,p = 0.004) were observed between the primary failure group and effective group.
CONCLUSIONS: RF+ JIA required bDMARDs with high probability. JIA with high titre of RF tends to be refractory to anti-TNFα agents. Tocilizumab or abatacept could be a first-choice bDMARD in such cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Modern rheumatology - 33(2023), 6 vom: 01. Nov., Seite 1171-1175 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamasaki, Yuichi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.11.2023 Date Revised 08.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/mr/roac125 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347131530 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347131530 | ||
| 003 | DE-627 | ||
| 005 | 20231226033120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/mr/roac125 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347131530 | ||
| 035 | |a (NLM)36197747 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamasaki, Yuichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rheumatoid factor value for determining the first biologic agent to use for non-systemic juvenile idiopathic arthritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2023 | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Japan College of Rheumatology 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVES: Currently, no indicators on which biologic disease-modifying anti-rheumatic drugs (bDMARDs) should be used first for juvenile idiopathic arthritis (JIA) have been established. Thus, this study aimed to determine the useful biomarkers in JIA to enable the best selection of the first bDMARDs without primary failure | ||
| 520 | |a METHODS: This retrospective study used data of patients examined for JIA between 2015 and 2021 at Kagoshima University Hospital in Japan | ||
| 520 | |a RESULTS: Altogether, 67 cases of non-systemic JIA were analyzed, excluding cases that had been treated for <6 months. Of the 67 cases, 52 were treated with bDMARDs and all rheumatoid factor (RF)+ types (32 cases) were treated with bDMARDs. Eleven cases (31.4&) (all were RF+ types and used anti-tumor necrosis factor (TNF)α agents) switched to other bDMARDs because of primary failure, and nine cases had secondary failure (6;anti-TNF, 3;anti-Interleukin-6). A significant difference in pre-treatment RF values (177.9 vs 25.7 IU/ml, p = 0.002) and presence (Odds Ratio 1.952,p = 0.004) were observed between the primary failure group and effective group | ||
| 520 | |a CONCLUSIONS: RF+ JIA required bDMARDs with high probability. JIA with high titre of RF tends to be refractory to anti-TNFα agents. Tocilizumab or abatacept could be a first-choice bDMARD in such cases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a First biologic disease-modifying anti-rheumatic drugs | |
| 650 | 4 | |a non-systemic juvenile idiopathic arthritis | |
| 650 | 4 | |a polyarthritis | |
| 650 | 4 | |a primary failure | |
| 650 | 4 | |a rheumatoid factor | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 650 | 7 | |a Rheumatoid Factor |2 NLM | |
| 650 | 7 | |a 9009-79-4 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Nakamura, Aki |e verfasserin |4 aut | |
| 700 | 1 | |a Kubota, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Mitsunobu, Takuro |e verfasserin |4 aut | |
| 700 | 1 | |a Moriyama, Mizuki |e verfasserin |4 aut | |
| 700 | 1 | |a Takei, Syuji |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Yasuhiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Modern rheumatology |d 2000 |g 33(2023), 6 vom: 01. Nov., Seite 1171-1175 |w (DE-627)NLM162086628 |x 1439-7609 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:6 |g day:01 |g month:11 |g pages:1171-1175 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/mr/roac125 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 6 |b 01 |c 11 |h 1171-1175 | ||